PRODH Regulates Tamoxifen Resistance through Ferroptosis in Breast Cancer Cells.

ABSTRACT:

Background

Estrogen receptor-positive breast cancer accounts for around 70% of all cases. Tamoxifen, an anti-estrogenic inhibitor, is the primary drug used for this type of breast cancer treatment. However, tamoxifen resistance is a major challenge in clinics. Metabolic reprogramming, an emerging hallmark of cancer, plays a key role in cancer initiation, progression, and therapy resistance. The metabolism of non-essential amino acids such as serine, proline, and glutamine is involved in tumor metabolism reprogramming. Although the association of glutamine metabolism with tamoxifen resistance has been well established, the role of proline metabolism and its critical enzyme PRODH is unknown.

Objective

The aim of this study is to explore the role and mechanism of PRODH in tamox

SUBMITTER: Zhang P 

PROVIDER: S-EPMC11507086 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature